Location
University of Colorado Anschutz Medical Campus, Aurora, CO
Fellowship Dates
July 1, 2023 – June 30, 2024
Deadline for Application
None – Rolling application process until position is filled
Notification Date
Prior to March 1, 2023
Location
University of Colorado Anschutz Medical Campus, Aurora, CO
Fellowship Dates
July 1, 2023 – June 30, 2024
Deadline for Application
None – Rolling application process until position is filled
Notification Date
Prior to March 1, 2023
Provide physicians with a strong foundation in clinical and translational research
Activities
Duration
1-2 years, 100% research
Candidates
Residents/fellows (PGY ≥ 2) in medicine or surgery
Contact
Email expression of interest and CV to:
Mark Nehler, MD
Professor of Surgery – Vascular
Program Director, Surgery Residency, University of Colorado
Train the next generation of vascular medicine specialists
Activities
Duration
Year 1, 60% clinical, 40% research
Optional Year 2, 100% research
Candidates
Completing medical residency or cardiology fellowship
Contact
Email expression of interest and CV to:
Kevin Rogers, MD
Associate Professor of Medicine
Director, Vascular Medicine Fellowship, University of Colorado
Marc Bonaca, MD, MPH
Professor of Medicine, University of Colorado
Executive Director, CPC Clinical Research
Click here to learn more about the University of Colorado Vascular Medicine Fellowship
Interviews with our current fellows, Mario Canonico, MD and Robert Wilson King, MD, and Mark Nehler, MD, Professor of Surgery.
Canonico ME, Hsia J, Guthrie N L …Bonaca M P (2022). Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial. Clinical Cardiology, 10.1002/clc.23853
Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) are underutilized in 2021 in patients with heart failure with or without diabetes (abstr). Diabetes 1 June 2022; 71 (Supplement_1): 868–P
Canonico ME, Hsia J Hess CN, Bonaca MP. Guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease (PAD)(abstr). Vasc Med, in press
Canonico ME, Capell W, Anand SS…Bonaca MP. Causes of Death in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD (abstr). Circulation, in press
Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) are underutilized in 2021-22 in patients with heart failure without diabetes (abstr). Circulation, in press
Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) for heart failure are underutilized in 2021-2 in patients with chronic kidney disease (abstr), J Am Soc Nephrol, in press
Hogan SE, Nehler MR, Anand S….King RW…Bonaca MP. (2022). Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med, 1358863X221085606
King RW, Bonaca MP. (2021). Acute aortic syndromes: a review of what we know and future considerations. Eur Heart J. Acute CV Care 10(10),1197–1203 https://doi.org/10.1093/ehjacc/zuab106
King RW, Nehler M. R., Patel MR…Bonaca MP. (2022) Risk Stratification for Amputation in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD (abstr). Circulation, in press
Hogan SE …Buchanan, C… Bonaca MP. (2022). Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med, 1358863X221085606
Hess CN, Nehler MR, Morrison JT, Buchanan C… Bonaca M.P. Pragmatic Implementation Science in Peripheral Artery Disease: Design and Conduct of OPTIMIZE PAD-1 (abstr), Vasc Med, in press
Buchanan C, Hogan SE..Hsia J. Exercise therapy for symptomatic peripheral artery disease following surgical and endovascular peripheral revascularization: could we do better? (abstr) Vasc Med, in press
Buchanan CE, Szarek M, Debus ES… Bonaca MP. Lower May Not Be Better: Systolic Blood Pressure and Risk of Major Adverse Limb Events in Patients with Symptomatic Peripheral Artery Disease after Revascularization: Insights from VOYAGER PAD (abstr). Circulation, in press
Debus, ES, Nehler MR, Govsyeyev N…Bonaca, M. P. (2021). Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation 144(14),1104–1116
Govsyeyev N, Malgor RD, Hoffman C et al. (2021). A systematic review and meta-analysis of outcomes after acute limb ischemia in patients with cancer. J Vasc Surg 74(3), 1033–1040.e1
Govsyeyev N, Nehler MR, Hiatt WR, Bonaca MP. (2020). Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Current Cardiol Rep 22(3), 13
Govsyeyev N, Nehler MR, Low Wang CC… Bonaca MP. (2022). Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg 75(2), 660–670.e3